Data protection Impressum

Life sciences

Researchers at EPFL, with colleagues from the University of Geneva, Geneva University Hospitals and Zurich, have developed VirTues, an AI foundation model for tissue biology that analyzes tumor tissue across many cancer types, with results published in Nature.

EPFL’s VirTues AI model maps tumor tissue across cancer types

17 August 2026

AB2 Bio has received a USD 30 million payment after Japanese pharmaceutical company Nippon Shinyaku exercised its option to commercialize Tadekinig alfa in the United States, with up to USD 600 million in further milestone and royalty payments.

AB2 Bio receives USD 30 million as Nippon Shinyaku takes up US rights

3 August 2026

MoleSense and Impli, both based at the Biopôle life sciences campus, have been selected by Germany's Federal Agency for Breakthrough Innovation to develop biosensors capable of continuously measuring at least four hormones over seven days.

MoleSense and Impli selected for the SPRIND Challenge on continuous hormone monitoring

3 August 2026

Immitra Bio, based in Plan-les-Ouates in the canton of Geneva, has closed an upsized CHF 2.4 million pre-seed round to advance its scalable in-vivo gene editing platform and its lead candidate for an inherited anemia.

Immitra Bio raises CHF 2.4 million to advance its in-vivo gene editing platform

3 August 2026

HeroSupport, a Geneva-based medtech company, has announced that NYU Grossman School of Medicine is the first clinical site in the United States to participate in its SHIELD study evaluating the VENUS SHELL breast immobilization device.

HeroSupport opens its first US clinical site for the SHIELD study

3 August 2026

Pilatus Biosciences, a Biopôle-based biotech whose lead therapy originated in research conducted in Lausanne, has established a subsidiary in Hong Kong and received regulatory approval to begin a clinical trial of PLT012 in patients with advanced solid tumors.

Pilatus Biosciences takes its Lausanne-born immunotherapy to Hong Kong

3 August 2026

The .NeuroRestore center in Lausanne, led by Jocelyne Bloch and Grégoire Courtine, has been honored with the 2026 Grand Prix scientifique of the NRJ Foundation - Institut de France for its brain-spine interface that restores movement to paralyzed patients.

.NeuroRestore wins part of France’s 2026 NRJ Foundation science grand prix

13 July 2026

Carewell, a Lausanne-based start-up whose platform helps Swiss healthcare institutions manage staff shortages, has raised CHF 1.5 million in a seed round to accelerate its expansion across Switzerland.

Carewell raises CHF 1.5 million to manage healthcare staff shortages

6 July 2026

Geneva has been named European Capital of Brain Health 2026 by the European Academy of Neurology, in recognition of its research and innovation ecosystem.

Geneva named European Capital of Brain Health 2026

6 July 2026

AC Immune will receive a USD 4 million research grant from The Vijay and Marie Goradia Charitable Foundation to extend Part 1 of the Phase 2 VacSYn trial of ACI-7104, its immunotherapy for early Parkinson's disease.

AC Immune secures USD 4 million grant to advance its Parkinson’s immunotherapy

6 July 2026

1 2 3 4 5 6 … 30